Latest Syntara (Asx:Snt) News

Page 2 of 2
Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.
Ada Torres
Ada Torres
13 June 2025
Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.
Ada Torres
Ada Torres
13 June 2025
Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.
Ada Torres
Ada Torres
13 June 2025
Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.
Ada Torres
Ada Torres
10 June 2025
Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.
Ada Torres
Ada Torres
30 Apr 2025
Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.
Victor Sage
Victor Sage
29 Jan 2025
Syntara Limited reported a robust $11.35 million increase in cash during the December 2024 quarter, underpinned by government grants and steady operational inflows. The company closes the period with a strong cash position of $18.07 million, signaling financial resilience.
Sophie Babbage
Sophie Babbage
29 Jan 2025